For veterans who have cycled through medications, counseling and other treatments only to find that severe depression remains, the Department of Veterans Affairs is examining a dramatically different possibility. Psilocybin, the psychedelic compound best known as the active ingredient in certain mushrooms, is entering a controlled VA clinical trial designed specifically for veterans with treatment-resistant major depression, including those who are also living with post-traumatic stress disorder.
The research places the VA squarely inside a rapidly developing area of American medicine that only a generation ago would have been difficult to imagine within a federal hospital system. Psychedelic compounds are increasingly being studied under tightly regulated clinical conditions for serious mental health disorders, and the VA is now examining whether psilocybin can produce measurable benefits for veterans whose depression has not responded adequately to existing treatment.
The new study is called PIVOT, short for Psilocybin Intervention for Veterans Overcoming Treatment-Resistant Depression. Rather than testing psilocybin broadly among veterans experiencing depression, researchers are concentrating on patients facing some of the more persistent forms of the illness. Veterans diagnosed with treatment-resistant major depressive disorder may qualify for the randomized, controlled trial whether or not they also have PTSD.
Participants will receive one of two psilocybin dosage levels, allowing researchers to compare outcomes while examining changes in depression before and after treatment. Investigators will also evaluate side effects, tolerability and participants’ own reports about the severity of their depression. Those measurements are intended to determine whether improvements occur, how significant they may be and what risks accompany treatment.
Nothing about the trial resembles unsupervised psychedelic use. The psilocybin will be pharmaceutical grade and administered in controlled clinical environments under strict quality and safety procedures developed with the Food and Drug Administration. Psychological support will also be incorporated into the clinical setting, giving researchers the ability to observe participants and respond to potential physical or psychological complications.
That controlled environment is central to understanding what the VA is doing. The department is not recommending psilocybin for veterans generally, and the substance has not been approved as a routine VA treatment. The government is testing a potential therapy through the clinical research process, where effectiveness and risk must be established through evidence before a treatment can move toward wider medical use.
The trial stretches across several regions of the country. Veterans will be studied through the Birmingham VA Health Care System and Tuscaloosa VA Medical Center in Alabama, VA Portland Health Care System in Oregon, Corporal Michael J. Crescenz VA Medical Center in Philadelphia and VA Puget Sound Health Care System in Seattle. Conducting the research within established VA medical systems also places participants inside facilities already experienced in treating veterans with complicated physical and mental health needs.
“Far too many Veterans are living with mental health conditions that don’t respond to available treatments,” VA Secretary Doug Collins said. “Under President Trump, VA is pursuing all avenues to evaluate new treatments and offer meaningful relief for those who have worn the uniform.”
PIVOT is not an isolated experiment. The VA says it is involved in 20 active clinical trials examining psychedelic therapies for mental health conditions, an indication of how substantially the research landscape has changed. Compounds including psilocybin, MDMA and LSD are receiving scientific attention as researchers investigate whether their effects can be harnessed therapeutically under carefully controlled conditions.
Federal regulators are examining that research as well. The FDA has granted breakthrough therapy designation to several companies developing treatments involving psychedelic substances, including psilocybin, MDMA and LSD. The designation can help accelerate development and regulatory review of potentially important therapies, but it does not constitute approval and does not establish that a drug has been proven safe or effective for general clinical use.
For the VA, that regulatory threshold remains firm. Psychedelic therapies will not be considered for ordinary clinical use within the veterans health system unless they receive FDA approval. Until then, their place within VA medicine remains research rather than routine treatment.
The department is also warning veterans against interpreting the expanding research as an invitation to experiment independently. VA officials strongly discourage self-medicating with psychedelics, abandoning existing mental health treatment or using unprescribed substances in an attempt to reproduce what occurs during a clinical study. Veterans considering any change to their mental health care are being advised to speak with their health care providers and continue using established treatments unless changes are made under appropriate medical supervision.
The federal push into psychedelic research is occurring alongside a broader effort to accelerate the development of treatments for serious mental illness. President Donald Trump has directed federal agencies to pursue measures intended to increase participation in clinical trials and advance innovative research models and potential drug approvals involving psychedelic compounds. The VA trial brings veterans directly into that expanding field of investigation while maintaining the regulatory safeguards governing federal medical research.
For veterans with treatment-resistant depression, the importance of the research lies less in the unusual history of the drug than in the unanswered medical question before researchers. When established treatments have failed to provide sufficient relief, medicine must determine whether another scientifically defensible option exists and whether its potential benefits outweigh its risks.
Psilocybin has not yet answered that question. The PIVOT trial is designed to help do so.
What happens inside these VA treatment rooms could therefore reach well beyond a single experimental drug. The research will contribute to a larger body of evidence determining whether psychedelic-assisted therapies can earn a legitimate place in modern mental health care. For veterans who have exhausted conventional approaches without achieving adequate improvement, that investigation represents something more concrete than enthusiasm surrounding a controversial compound: a carefully controlled attempt to find out whether another treatment can actually work.